Nuovi approfondimenti nella ricerca su l'ateroslerosi: LOX-1, un primo attore nelle malattie cardiovascolari

Translated title of the contribution: New insights in atherosclerosis research: LOX-1, leading actor of cardiovascular diseases

Giuseppe Novelli, R. Mango, L. Vecchione, E. Mariotti, P. Borgiani, J. L. Mehta, F. Romeo

Research output: Contribution to journalArticle

Abstract

The OLR1 gene encodes a cell-surface endocytosis receptor (LOX-1) for oxidized low density lipoprotein (OxLDL). LDL is oxidized in vascular endothelial cells to a highly injurious product that results in endothelial cell injury, which is implicated in the development of atherosclerosis. Vascular endothelial cells also internalize and degrade oxLDL though the OLR1 receptor. This receptor is upregulated by ox-LDL itself and by angiotensin II, endothelin, cytokines, and shear stress, important factors of atherosclerosis. This receptor is upregulated in the arteries of hypertensive, dyslipidemic, and diabetic animals. Two independent studies have demonstrated genetic association between polymorphisms in the OLR1 gene and myocardial infarction. Based on genetic and functional studies we propose LOX-1 as a novel biomarker and target in cardiovascular disease diagnosis and prevention.

Translated title of the contributionNew insights in atherosclerosis research: LOX-1, leading actor of cardiovascular diseases
Original languageItalian
Pages (from-to)239-248
Number of pages10
JournalClinica Terapeutica
Volume158
Issue number3
Publication statusPublished - May 2007

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'New insights in atherosclerosis research: LOX-1, leading actor of cardiovascular diseases'. Together they form a unique fingerprint.

  • Cite this

    Novelli, G., Mango, R., Vecchione, L., Mariotti, E., Borgiani, P., Mehta, J. L., & Romeo, F. (2007). Nuovi approfondimenti nella ricerca su l'ateroslerosi: LOX-1, un primo attore nelle malattie cardiovascolari. Clinica Terapeutica, 158(3), 239-248.